F Marc LaForce

Summary

Affiliation: Program for Appropriate Technology in Health
Country: USA

Publications

  1. ncbi The Meningitis Vaccine Project
    F Marc LaForce
    The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney Voltaire, France
    Vaccine 25:A97-100. 2007
  2. ncbi Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
    F Marc LaForce
    PATH, 13 Chemin du Levant, Ferney Voltaire 01210, France
    Vaccine 27:B13-9. 2009
  3. ncbi Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  4. ncbi Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
    Montse Soriano-Gabarro
    Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Health Popul Nutr 22:275-85. 2004
  5. ncbi The promise of conjugate vaccines for Africa
    Marie Paule Kieny
    Initiative for Vaccine Research, World Health Organization, Av Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 25:A108-10. 2007
  6. ncbi From genomics to surveillance, prevention and control: new challenges for the African meningitis belt
    Jean-Michel Alonso
    Institut Pasteur, National Reference Centre for Meningococci, Neisseiria Unit, Department of Molecular Medicine, Paris, France
    Vaccine 24:4279-84. 2006
  7. ncbi Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Nilima Kshirsagar
    Seth G S Medical College and KEM Hospital Parel, Mumbai, India
    Vaccine 25:A101-7. 2007

Collaborators

Detail Information

Publications7

  1. ncbi The Meningitis Vaccine Project
    F Marc LaForce
    The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney Voltaire, France
    Vaccine 25:A97-100. 2007
    ..The MVP model is a clear example of the usefulness of a "push mechanism" to finance the development of a needed vaccine for the developing world...
  2. ncbi Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
    F Marc LaForce
    PATH, 13 Chemin du Levant, Ferney Voltaire 01210, France
    Vaccine 27:B13-9. 2009
    ..Widespread use of such a vaccine is likely to generate herd immunity and to put an end to Group A meningococcal epidemics...
  3. ncbi Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  4. ncbi Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
    Montse Soriano-Gabarro
    Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Health Popul Nutr 22:275-85. 2004
    ..Other studies will include evaluations of safety, vaccine coverage, impact on carriage and herd immunity, and prevention-effectiveness studies...
  5. ncbi The promise of conjugate vaccines for Africa
    Marie Paule Kieny
    Initiative for Vaccine Research, World Health Organization, Av Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 25:A108-10. 2007
    ..A review of the evidence in order to analyse how to optimize immunization schedules for conjugate vaccines is warranted...
  6. ncbi From genomics to surveillance, prevention and control: new challenges for the African meningitis belt
    Jean-Michel Alonso
    Institut Pasteur, National Reference Centre for Meningococci, Neisseiria Unit, Department of Molecular Medicine, Paris, France
    Vaccine 24:4279-84. 2006
  7. ncbi Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Nilima Kshirsagar
    Seth G S Medical College and KEM Hospital Parel, Mumbai, India
    Vaccine 25:A101-7. 2007
    ..This opens the prospective for further development and licensure of this vaccine to eliminate epidemic meningitis in sub-Saharan Africa...